Skip to content
Buy This GLP
← Research
Evidence

GLP-1 Drugs in Idiopathic Intracranial Hypertension: A Four-Study Meta-Analysis

A small exenatide trial measured lower pressure. A four-study review found associations with less papilledema, with limited evidence from randomized trials.

Editorial profile: Neil SandersBuy This GLP Editorial Team3 min read
Relative risk against standard care1.0papilledemavisual disturbanceheadacheEstimates come from different study subsets.

Because weight is relevant to idiopathic intracranial hypertension, weight loss with GLP-1 drugs offers one reason to study these medicines. Researchers have also tested whether a drug can lower pressure directly.

What the pressure trial measured

A small trial randomized 15 women with active disease to exenatide or placebo [2]. The researchers measured pressure directly. It was lower with exenatide at 2.5 hours and 24 hours. The 12-week result met the trial's prespecified threshold of p<0.10, with p=0.058.

The study was too small to establish long-term benefit or explain how pressure changed. An uncertain result for body mass index cannot establish whether weight played a role.

What the pooled studies found

The 2025 review covered 1,550 patients across a trial, a nonrandomized study and two registry studies [1]. Different subsets contributed to different outcomes. The estimated relative risk for papilledema was 0.25 (95% CI 0.15 to 0.43). Papilledema means swelling of the optic disc.

The headache risk estimate was imprecise. It ranged from a substantial reduction to a slight increase. The studies reported digestive symptoms, with limited evidence to estimate uncommon or long-term harms.

Suspected intracranial hypertension needs clinical assessment. Treatment decisions depend on symptoms, pressure and the risk to vision.

Frequently asked

Can GLP-1 drugs lower intracranial pressure?
A small randomized trial found lower pressure with exenatide than with placebo. Larger studies would help establish whether the effect lasts.
Did the review establish that GLP-1 drugs protect vision?
The review reported associations with less papilledema and fewer visual problems. Most of the evidence came from nonrandomized studies.

Sources

  1. [1] Stefanou MI, et al. (2025). Efficacy and Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis European Journal of Neurology. PMID 40937960
  2. [2] Mitchell JL, Lyons HS, Walker JK, et al. (2023). The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial Brain. PMID 36907221

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence